Advair Bioequivalence Guidance Falls Short of GSK’s Requests

FDA’s draft guidance requires clinical study but sets a lower bar to generics of GSK’s blockbuster asthma and COPD treatment than company proposed; standards appear poised for warm reception from generic challengers.